Compare · ABOS vs BNTX
ABOS vs BNTX
Side-by-side comparison of Acumen Pharmaceuticals Inc. (ABOS) and BioNTech SE (BNTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABOS and BNTX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BNTX is the larger of the two at $24.93B, about 154.3x ABOS ($161.6M).
- Over the past year, ABOS is up 42.7% and BNTX is up 0.6% - ABOS leads by 42.0 points.
- BNTX has been more active in the news (13 items in the past 4 weeks vs 2 for ABOS).
- BNTX has more recent analyst coverage (25 ratings vs 12 for ABOS).
- Company
- Acumen Pharmaceuticals Inc.
- BioNTech SE
- Price
- $2.24+0.22%
- $98.61-0.70%
- Market cap
- $161.6M
- $24.93B
- 1M return
- -25.58%
- -12.38%
- 1Y return
- +42.68%
- +0.64%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2019
- News (4w)
- 2
- 13
- Recent ratings
- 12
- 25
Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapeutics for the treatment of Alzheimer's and other neurodegenerative diseases. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, which is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is based in Charlottesville, Virginia.
BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Latest ABOS
- Acumen Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026
- Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
- SEC Form S-8 filed by Acumen Pharmaceuticals Inc.
- SEC Form 10-Q filed by Acumen Pharmaceuticals Inc.
- Acumen Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights
- Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026
- Director Porter Derrell exercised 19,500 shares at a strike of $1.07 and sold $75,240 worth of shares (32,300 units at $2.33), decreasing direct ownership by 27% to 35,500 units (SEC Form 4)
- SEC Form 144 filed by Acumen Pharmaceuticals Inc.
Latest BNTX
- Chief Executive Officer Sahin Ugur sold $6,842,742 worth of Ordinary Shares (69,000 units at $99.17) as part of a pre-agreed trading plan, decreasing direct ownership by 17% to 341,209 units (SEC Form 4)
- Chief Executive Officer Sahin Ugur sold $7,860,757 worth of Ordinary Shares (79,000 units at $99.50) as part of a pre-agreed trading plan, decreasing direct ownership by 16% to 410,209 units (SEC Form 4)
- Chief Executive Officer Sahin Ugur sold $6,239,071 worth of Ordinary Shares (64,000 units at $97.49) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 489,209 units (SEC Form 4)
- SEC Form 6-K filed by BioNTech SE
- Chief Executive Officer Sahin Ugur sold $4,721,976 worth of Ordinary Shares (49,000 units at $96.37) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 553,209 units (SEC Form 4)
- A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
- Chief Executive Officer Sahin Ugur sold $8,439,336 worth of Ordinary Shares (86,000 units at $98.13) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 602,209 units (SEC Form 4)
- SEC Form 6-K filed by BioNTech SE
- BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients
- Chief Executive Officer Sahin Ugur sold $1,974,287 worth of Ordinary Shares (20,500 units at $96.31) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 688,209 units (SEC Form 4)